investing.com /2 weeks ago

Bristol Myers Squibb presents 56-week Camzyos trial data

Read source
seekingalpha.com /3 weeks ago

Bristol-Myers Squibb: Progress On The Bridge, But The Patent Cliffs Remain (Rating Downgrade)

Read source
pharmexec.com /3 weeks ago

<![CDATA[Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial ]]>

Read source
roi-nj.com /1 week ago

Bristol Myers Squibb announces unified research and development organization

Bristol Myers Squibb said on Nov. 12 that Cristian Massacesi will lead a combined, end-to-end research and development organization, effective Jan. 1, 2027. As part of this planned...

Read source
biopharmadive.com /1 month ago

Bristol Myers dips on ‘confounding’ lung drug results

Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects.

Read source
roi-nj.com /4 weeks ago

Bristol Myers Squibb reports interim MS data from CAR T study

Bristol Myers Squibb announced Oct. 23 interim safety and efficacy results from a Phase 1 study evaluating an investigational CAR T cell therapy in patients with highly active rela...

Read source
cafepharma.com /2 weeks ago

Your favorite BMS experience - list here!

Your favorite BMS experience - list here! Anonymous (not verified) Fri, 11/06/2026 - 18:33 field_thread_url https://cafepharma.com/boards/threads/your-favo...

Read source
fool.com /4 weeks ago

Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue

Pfizer's revenue swung sharply lower before stabilizing, while Bristol Myers Squibb kept climbing steadily—a divergence that matters for long-term investors.

Read source
pharmexec.com /3 weeks ago

<![CDATA[Pharmaceutical Executive Daily: Pathos AI Enters Collaboration with Bristol Myers Squibb]]>

Read source
biopharmadive.com /1 month ago

Bristol Myers trial revisions shake confidence in new class of fibrosis drugs

A spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol Myers’ admilparant — though it’s unc...

Read source
fool.com /2 weeks ago

Wall Street Is Ignoring Bristol Myers Squibb's Cash Machine -- and That's an Opportunity for Income Investors

Bristol Myers Squibb has a 4% yield and a 55% payout ratio, which should greatly interest dividend lovers.

Read source
fool.com /1 month ago

Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Bristol Myers Squibb recovered to $7.1B in net income while Eli Lilly more than doubled profits to $20.6B, a stark contrast in momentum that reshapes the value-versus-growth debate...

Read source
fool.com /1 month ago

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

Bristol Myers Squibb trades at a steeper discount despite higher leverage, while Novo Nordisk commands a premium on exceptional profitability and GLP-1 dominance.

Read source
law360.com /4 days ago

Cancer Drug Buyers Say BMS 'Invented' Args To Allow Appeal

Humana, Cigna, Walgreen Co. and an array of other employee benefit plans, insurers and hospitals have urged a federal judge not to let Bristol-Myers Squibb and generic-drug makers...

Read source
pharmexec.com /3 weeks ago

<![CDATA[ Pathos Ai Enters Drug Development Collaboration with Bristol Myers Squibb and Tempus Ai ]]>

Read source
law360.com /3 weeks ago

Bristol-Myers, Others Appeal Revlimid MDL To 3rd Circ.

Bristol-Myers Squibb, Natco Pharma, AbbVie and other pharmaceutical companies have sought permission to file an interlocutory appeal for a sprawling antitrust multidistrict litigat...

Read source
fool.com /1 month ago

Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

Amgen boasts stronger revenue growth, while Bristol Myers Squibb generates nearly 60% more free cash flow at half the valuation.

Read source
fool.com /3 weeks ago

Should You Buy Bristol Myers Squibb While It Trades Below 10 Times Forward Earnings?

Bristol Myers Squibb is facing a sizable patent cliff, but that's not unusual in the pharma sector.

Read source
fool.com /1 month ago

Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient N...

Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks com...

Read source
law360.com /1 month ago

Bristol-Myers, Natco And More Can't Ditch Cancer Drug MDL

A New Jersey federal judge Tuesday refused to throw out sprawling antitrust multidistrict litigation over Celgene Corp.'s cancer drug Revlimid filed against Bristol-Myers Squibb, N...

Read source
pharmexec.com /1 month ago

<![CDATA[Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Cl...

Read source
cafepharma.com /1 week ago

BMS layoffs 2026

BMS layoffs 2026 Anonymous (not verified) Thu, 11/12/2026 - 21:38 field_thread_url https://cafepharma.com/boards/threads/bms-layoffs-2026.713612/...

Read source
fool.com /1 month ago

3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation

With this pharma company trading for less than 10 times earnings, the market remains very uncertain about its stock and looming patent cliff.

Read source
pharmexec.com /2 weeks ago

<![CDATA[Roundup: Boehringer Ingelheim Licenses Six Oncology Programs From Sino Biopharmaceutical, Nxera Licenses EP4...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.